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Reports focusing on the immunological microenvi-
ronment of peripheral T-cell lymphomas (PTCL) are
rare. Here we studied the reciprocal contribution
of regulatory (Treg) and interleukin-17-producing
(Th17) T-cells to the composition of the lymphoma-
associated microenvironment of angioimmunoblastic
T-cell lymphoma (AITL) and PTCL not otherwise spec-
ified on tissue microarrays from 30 PTCLs not other-
wise specified and 37 AITLs. We found that Th17 but
not Treg cells were differently represented in the two
lymphomas and correlated with the amount of mast
cells (MCs) and granulocytes, which preferentially
occurred in the cellular milieu of AITL cases. We ob-
served that MCs directly synthesized interleukin-6
and thus contribute to the establishment of a pro-
inflammatory, Th17 permissive environment in AITL.
We further hypothesized that the AITL clone itself
could be responsible for the preferential accumula-
tion of MCs at sites of infiltration through the synthe-
sis of CXCL-13 and its interaction with the CXCR3 and
CXCR5 receptors expressed on MCs. Consistent with
this hypothesis, we observed MCs efficiently migrat-
ing in response to CXCL-13. On these bases , we
conclude that MCs have a role in molding the im-
munological microenvironment of AITL toward the
maintenance of pro-inflammatory conditions prone
to Th17 generation and autoimmunity. (Am J Pathol
2010, 177:792–802; DOI: 10.2353/ajpath.2010.091286)
T-cell neoplasms remain largely obscure due to their
relatively low prevalence and little knowledge of their
pathobiology.1 Studies on peripheral T-cell lymphomas
(PTCL) have focused on the identification of their normal
counterparts, clone-specific signatures and clone-related
molecules with possible prognostic and/or therapeutic rele-
vance.2–4 By contrast, few studies have investigated the T-cell
lymphoma-associated microenvironment with the aim of find-
ing diagnostic criteria to distinguish the various PTCL.5–7
Among PTCL, PTCL not otherwise specified (PTCL/
NOS) and angioimmunoblastic T-cell lymphoma (AITL)
are the most common entities presenting with lymph
node involvement.8 Although both forms are character-
ized by a dismal prognosis and poor response to stan-
dard chemotherapy, their distinction is mandatory be-
cause different targets for specific therapies have been
recently proposed.9
According to the gene-expression profile of neoplastic
clones, a follicular helper T-cell (Tfh)-related signature
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has been highlighted in AITL, whereas a much more
heterogeneous one has been described in PTCL/
NOS.2,3,9,10 Such differences are paralleled by a different
organization of the lymphoma-associated microenviron-
ment. Indeed, the presence of high-endothelial venule
proliferation, follicular dendritic cell hyperplasia, and
large B-cell and granulocyte infiltration characterize AITL
allowing histopathological distinction from PTCL/NOS.8
The tumor-associated microenvironment is a complex
network of cellular and molecular interactions in which
cells of the innate and adaptive immunity play a primary
role. In this setting, a specific subset of T lymphocytes,
the regulatory T-cells (Treg), has been demonstrated to
actively influence the immunological environment asso-
ciated to neoplasms by hindering anti-tumoral immun-
ity.11,12 The recent evidence of a functional plasticity of
Treg, along with the identification of interleukin (IL)-17-
producing Th cells (Th17) that can differentiate from Treg
and are active in promoting inflammation and autoimmu-
nity, added a further degree of complexity to the issue of
the tumor/environment interactions.13,14
To date, studies investigating the reciprocal contribu-
tion of Treg and Th17 to PTCL-associated environment
are lacking. Here we studied the involvement of Tregs and
Th17 in the composition of AITL and PTCL/NOS microenvi-
ronment. We found a prevalence of Th17 cells in AITL
cases, and correlated it with the preferential accumulation
of mast cells in this lymphoma. We suggest a possible
mechanism through which AITL lymphoma cells could re-
cruit mast cells and in turn favor Th17 polarization.
Materials and Methods
Cell Lines, Reagents, and Antibodies
The human B-cell lymphoma cell line BJAB (Epstein Barr
Virus noninfected) was maintained in RPMI supple-
mented with 10% heat-inactivated fetal bovine serum in a
humid atmosphere at 37°C and 5% CO2 with 50 U/ml
penicillin and 50 g/ml streptomycin. All reagents were
from EuroClone s.p.a. (Pavia, Italy). The human LAD2
mast cell line was kindly provided by A. Kirshenbaum
(NIH, Bethesda, MD). The cell line was established from
bone marrow aspirates of a patient with mast cell (MC)
leukemia.15 LAD2 cells were cultured in the serum-free
medium StemPro-34 (Invitrogen, Carlsbad, CA) contain-
ing 2 mmol/L glutamine and 100 ng/ml human stem-cell
factor (Peprotech Inc, Rocky Hill, NJ). The human endo-
thelial ADMEC cells were a kind gift of F. Tedesco, De-
partment of Life Sciences, University of Trieste (Trieste,
Italy).
For immunohistochemical and immunofluorescence
assays, the following primary antibodies were adopted:
mouse anti-human Foxp3 (clone 221 D/D3, AbD Serotec,
Oxford, UK), rabbit anti-human IL-17 (H-132, Santa Cruz
Biotechnology, Santa Cruz, CA), goat anti-human IL-6
(R&D Systems, Minneapolis, MN), rabbit anti-human
IL-21 (AbD Serotec), mouse anti-human IL-23 (clone HLT
2736, Biolegend, San Diego, CA), mouse anti-human
mast cell tryptase (clone 10D11, Novocastra, Newcastle,
UK), mouse anti-human OX40 (clone 102H6, Novocas-
tra), mouse anti-human CD4 (clone IF6, Novocastra), and
mouse anti-human CD25 (clone 4C9, Novocastra).
Sample Selection
PTCL/NOS and AITL cases for tissue microarray (TMA)
preparation were collected from the archives of the He-
matopathology Unit of the Department of Hematology
and Oncological Sciences, University of Bologna (Bolo-
gna, Italy). Overall, 34 PTCL/NOS and 39 AITL cases
were included in the study. Moreover, nine representative
AITL and nine PTCL/NOS cases were selected from the
archives of the Department of Human Pathology of the
University of Palermo to perform full-section detailed im-
munophenotypical characterization of Th17-related cyto-
kines, double immunohistochemistry and immunofluores-
cence assays, and co-localization analyses.
Tissue Microarray Preparation
For TMA construction, a H&E-stained slide was cut from
each paraffin-block and reviewed by two experienced he-
matopathologists (P.P.P. and S.A.P.). Representative tumor
regions were morphologically identified and marked on the
H&E-stained slides. Tissue cylinders with a diameter of 1
mm were punched from the marked areas of each block
and brought into a recipient paraffin block by using a pre-
cision instrument (Beecher Instruments, Silver Spring, MD)
as previously described.16 To overcome the problem of
tissue heterogeneity, each donor tissue block was punched
twice. Sections 4-m thick were cut from each TMA and
transferred to electrically charged slides.
Immunohistochemical Analyses
Single-marker immunohistochemistry was performed by
using the streptavidin-biotin-peroxidase complex method
(Strept-ABC) as previously reported.17 Either aminoethyl-
carbazole (red signal) or 3,31-Diaminobenzidine (DAB;
brown signal) was used as a chromogenic substrate, and
sections were counterstained with hematoxylin. Negative
control stainings were performed by using mouse, rabbit,
or goat immune sera instead of the primary antibodies
(Supplemental Figure S1 at http://ajp.amjpathol.org).
Double immunostaining was achieved by two consecu-
tive single rounds of immunohistochemistry by using Strept-
ABC and alkaline phosphatase anti-alkaline phosphatase
methods with DAB and FastRed (Dako, Glostrup, Denmark)
chromogens, respectively. Slides were evaluated under a
Leica DM2000 optical microscope (Leica Microsystems, Wet-
zlar, Germany) and microphotographs were collected by us-
ing a Leica DFC320 digital camera (Leica Microsystems).
Cell counts were visually performed on immuno-stained
TMA slides by counting the absolute number of immunore-
active cells out of four high-power fields (HPF; 400 mag-
nification) on each tissue core and then averaging the
counts of the two cores. Microvascular density (MVD) was
similarly assessed by counting the absolute number of
CD34 vascular structures. All of the cell counts on TMAwere
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independently performed by two pathologists (C.T. and
A.M.F.), and when the counts were discordant, the final score
was determined by averaging the individual scores.
MC/Th17 co-localization analysis was performed on
full-sections of the selected representative nine AITL and
nine PTCL cases following double-immunostaining for
mast cell tryptase and IL-17. To analyze the spatial co-
localization between mast cells and Th17 cells, in each
case four HPFs rich in MCs (ie, representative of the
highest MC density) and four HPFs almost devoid of MCs
were identified; the number of Th17 cells in these areas
was determined and the correlation between MC and
Th17 counts was calculated.
Immunofluorescence and Confocal Microscopy
For immunofluorescence analysis on confocal micros-
copy, the tissue sections were deparaffinized with xylene
and rehydrated to water through a graded alcohol series.
After microwave antigen retrieval, the samples were in-
cubated, by sequential immunostaining, with primary an-
tibodies anti-human IL-6 and anti-human Tryptase. After
Fc blocking, anti-IL-6 binding was revealed by Alexa
488-conjugated rabbit anti-goat (Invitrogen Molecular
Probes, Carlsbad, CA) secondary antibody, and
Tryptase was revealed by Alexa 568-conjugated rat anti-
mouse (Invitrogen Molecular Probes) secondary anti-
body. Nuclear staining was performed by incubation with
TOTO3 iodide (Invitrogen Molecular Probes). Slides were
evaluated by using a Leica TCS SP5 laser scanning
confocal microscope (Leica Microsystems).
Quantitative RT-PCR for CXCR3 and CXCR5
Total RNA was extracted from 107 cells by using Trizol
reagent (Invitrogen), following the manufacturer’s recom-
mendations. cDNA was obtained by using iScript cDNA
Synthesis kit (Bio-Rad, San Francisco, CA) starting from 1
g total RNA following the manufacturer’s instructions.
cDNA generated was amplified by quantitative real-time
PCR (with Bio-Rad iQ5 instrument) using iQTM SYBRGreen
Super Mix (Bio-Rad), and data analysis was performed by
using iQ5 optical system software (Bio-Rad). Glyceralde-
hyde-3-phosphate dehydrogenase (GADPH) gene was
used as normalizer in each sample. Primers were designed
with National Center for Biotechnology Information (NCBI)-
Primer Blast and sequences are as follows: GADPH for-
ward: 5-ACCACAGTCCATGCCATCAC-3; GADPH re-
verse: 5-TCCACCACCCTGTTGCTGTA-3; CXCR3 forward:
5-CATGGTCCTTGAGGTGAGTGA-3; CXCR3 reverse: 5-
TACAGCTAGGTGGAGCAGGAAG-3; CXCR5 forward:
5-CAGCCATGAACTACCCGCTAA-3; CXCR5 reverse:
5-GGCAGAGATGATTTTCCACCAG-3.
Chemotaxis Assay
Chemotaxis was performed in a 96-transwell insert
(Costar, Lowell, MA) with 8-m pore-size filters. In addi-
tion, 1  105 BJAB or LAD2 cells were plated in the upper
chamber and chemoattracted by increasing concentrations
of human recombinant CXCL13 (Peprotech). After 2 hours,
6 hours, and 24 hours, cell numbers in the upper and lower
chamber were counted and migration was calculated as
the percent of migrated cells over total cell count.
Gene Expression Analysis
We analyzed gene expression profile (GEP) data of 28
PTCL/NOS and six AITL derived from cryo-preserved
lymph nodes, and four samples of reactive lymph-nodes,
previously generated by using the Affymetrix HG-U133
2.0 plus microarray (Affymetrix, Inc., Santa Clara, CA)
and available at http://www.ncbi.nlm.nih.gov/projects/
geo/, last accessed April 2010. For technical details see
Piccaluga et al.9 In particular, we focused on the expres-
sion of selected cytokines known to be involved in Th17
polarization, such as IL-1b, IL-6, IL-17, IL-21, and IL-23. In
addition, the Th1 and Th2 cytokines interferon- and IL-4
were studied for control purposes. To avoid the possible puz-
zling effect of reactive components contained in tumor sam-
ples, cases with a content of neoplastic cells possibly higher
than or equal to the 90% value were selected.
Statistical Analysis
Comparison of data between AITL and PTCL/NOS cases
was performed by Student’s t-test for independent sam-
ples assuming statistical significance for P values below
0.05. Covariate analysis was performed by the means of
Spearman’s rank correlation coefficient (rho).
Results
IL-17 but Not Foxp3 T Cells Are Differentially
Represented in AITL and PTCL/NOS Cases
We analyzed the presence and amount of Foxp3 and
IL-17 cells in PTCL/NOS and AITL cases counting the total
number of stained cells out of four HPFs in TMAs. Overall, 37
out of 39 AITL and 30 out of 34 PTCL/NOS cases proved
adequate for immunohistochemistry quantitative analysis.
As already observed by Bonzheim et al,18 Foxp3
cells showed a scattered distribution in AITL and PTCL/
NOS cases and none of the evaluated cases displayed a
uniform reactivity to anti-Foxp3, supporting the reactive
nature of Treg infiltrating these lymphomas. A similar
distribution was displayed also by IL-17-expressing cells.
The amount of Foxp3 cells proved to be comparable in
the two lymphoma subtypes as the average number of
reactive cells was 35.8 (SD, 17.37) and 34.4 (SD, 15.92) in
PTCL/NOS and AITL, respectively (P  0.927; Figures 1
and 2, A and C). Interestingly, the frequency of IL-17 cells
was significantly higher in AITL (average, 10.02; SD, 5.28)
than in PTCL/NOS TMAs (average, 3.07; SD, 2.34; P 
0.001; Figures 1 and 2, B and D). Consequently, the aver-
age ratio between Foxp3 and IL-17 cells resulted higher
in PTCL/NOS than in AITL cases (9.61 vs. 4.16; P 0.001).
Double immunohistochemistry and immunofluorescence for
CD25/Foxp3 and CD4/IL-17 confirmed the Treg phenotype
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of infiltrating Foxp3 cells and the T-helper phenotype of
IL-17-expressing cells (not shown).
Expression of Th17-Related Cytokines in AITL
and PTCL Samples
Differentiation of human Th17 cells is the product of the
concomitant activity of several cytokines derived from
effector and regulatory immune cells both contributing to
the establishment of a pro-inflammatory environment.
These cytokines include transforming growth factor
(TGF)-, IL-1, IL-6, IL-21, and IL-23. Specifically, a key
role in inducing Th17 cells is played by IL-6, which is able
to counter TGF--driven regulatory T-cell program toward
IL-17 production, whereas IL-21 and IL-23 seem to be
mainly involved in the expansion and stabilization of Th17
cells rather than in their induction.19
The finding of a higher frequency of IL-17-expressing
cells in AITL cases as compared with PTCL/NOS ones
prompted us to investigate the expression of the key
cytokines implicated in the induction and maintenance of
IL-17-producing Th cells in the two lymphoma groups.
We thus analyzed the expression of IL-6, IL-21, and IL-23
by immunohistochemistry on TMAs, and extended such
analysis to full-sections from the selected representative
nine AITL and nine PTCL/NOS cases.
Interestingly, in both AITL and PTCL/NOS samples,
IL-6 was detected in medium-sized lymphoid cells show-
ing a dim expression (Figure 3, A and C, black arrows), in
vascular endothelia (Figure 3, A and C, green arrows),
and in scattered large cells with round-to-oval morphol-
ogy, which stained strongly with anti-IL-6 (Figure 3, A and
C, red arrows and inset). These latter cells showed a
difference in terms of frequency between AITL and PTCL/
NOS, being more abundant in AITL. A diffuse staining for
IL-21 was observed in lymphocytes from AITL cases
(Figure 3B, black arrows), whereas reactivity was con-
fined to scattered cells in PTCL/NOS cases (Figure 3D,
black arrows). Finally, IL-23 staining proved to be con-
fined to the Follicular Dendritic Cells (FDC) meshwork
(Figure 3, inset) in AITL cases and in areas with a higher
content of macrophages or foci of residual FDC in PTCL/
NOS ones.
On the basis of these results, we could conclude that the
environment of AITL is permissive for the induction and
expansion of Th17 cells since IL-6, IL-21, and IL-23 are
expressed. Moreover, the finding of a higher fraction of cells
with intense IL-6 reactivity in AITL suggested that IL-6 could
represent a clue for the preferential Th17 infiltration in AITL.
Differential mRNA Signatures in AITL and
PTCL/NOS Include Th17-Related Cytokines
Based on our data of the immunophenotypical expres-
sion of IL-17 and other cytokines related with Th17 po-
Figure 1. Frequency of Foxp3 and IL-17 cells in 30 PTCL/NOS and 37
AITL cases. The amount of Foxp3 cells is comparable in the two lymphoma
subgroups, whereas that of IL-17 cells is significantly higher in AITL.
Figure 2. A and C: Immunohistochemical expression of Foxp3 in two
representative cases of PTCL/NOS (A) and AITL (C) showing the scattered
distribution of immunoreactive cells. B and D: By immunohistochemistry,
IL-17-expressing cells display a scattered distribution and different frequency
in PTCL/NOS (B) and AITL (D) cases (Strept-ABC method with DAB chro-
mogenic substrate; original magnification, 100).
Figure 3. Immunohistochemical expression of IL-6 (A and C), IL-21 (B and
D), and IL-23 (inset) in representative AITL and PTCL/NOS cases. A and C:
IL-6 is expressed by vascular endothelia (green arrows), small lymphoid
cells (black arrows), and large cells showing intense staining (red arrows,
inset). B and D: IL-21 is diffusely expressed in AITL cells, whereas its
expression is confined to scattered lymphoid cells in PTCL/NOS (black
arrows). Inset: IL-23 expression is mainly confined to the dendritic cell/
macrophage meshwork (Strept-ABC method with DAB chromogen; original
magnification, 200; inset, 400).
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larization, we investigated whether the expression of
such key cytokines was related to the AITL and PTCL/
NOS signatures. To this purpose, we first analyzed the
GEPs previously generated from 28 representative cases
of PTCL/NOS and six cases of AITL9,20 by focusing on the
mRNA expression of IL-1, IL-6, IL-17, IL-21, and IL-23.
In addition, analysis of the Th1 and Th2 cytokines inter-
feron- and IL-4 was performed for control purposes.
The GEP analysis identified detectable levels of such
cytokines but failed to reveal significant differences in their
expression between PTCL/NOS and AITL. Nevertheless,
slightly higher values of IL-21 were recorded in AITL cases
(Supplemental Figure S2 at http://ajp.amjpathol.org). Simi-
lar results were observed by looking at the differential
molecular signatures of AITL and PTCL/NOS recently
described by de Leval et al.10 However, as GEP from our
cases actually relied on the neoplastic component, rep-
resenting more than 90% of the total cellularity in the vast
majority of cases,9 it is likely that the influence of reactive
components, including MCs and reactive T-lymphocytes,
was indeed limited. Importantly, when we considered a
recently published unselected series, which included
cases with abundant reactive components, the mRNA
signature differentiating AITL and PTCL/NOS cases ac-
tually included the cytokines IL-6, IL-21, and IL-23.21
Taken together, these results further supported the evi-
dence that Th17-related cytokines, though not belonging
to the AITL and PTCL/NOS clone signatures, were an
expression of different microenvironmental dynamics.
Mast Cells Represent a Relevant Source of IL-6
in AITL
We and others have recently demonstrated that mast
cells are able to directly interact with regulatory T-cells
giving rise to a complex bidirectional influence, which in
turn can affect both the effector function of MCs and Treg
suppressive program.22,23 In inflammatory conditions we
showed mast cells reverting the anergic and suppressive
status of Treg eventually promoting Th17 skewing
through IL-6 production and the OX40-OX40L axis.23 In
light of these evidences, we explored whether the medi-
um-to-large cells, characterized by strong IL-6 expres-
sion on immunohistochemistry and found differentially
present in AITL and PTCL/NOS, were mast cells. To this
purpose, double immunofluorescent confocal micros-
copy analysis was performed by using anti-IL-6 and anti-
mast cell tryptase antibodies. Strikingly, the population of
scattered cells with bright IL-6 expression showed co-
expression of mast cell tryptase, whereas cells with dim
IL-6 reactivity did not (Figure 4, A–F). This result sug-
gested that a relevant source of IL-6 in AITL was repre-
sented by mast cells, and that they likely accounted for
the differential fraction of IL-6-producing cells observed
in AITL and PTCL/NOS.
Mast Cells Preferentially Infiltrate the AITL
Environment and Correlate with the Amount
of Th17 Cells
To confirm the observation that mast cells, as IL-6 ex-
pressing cells, were more abundant in AITL as compared
with PTCL/NOS samples, we evaluated the number of
tryptase cells by immunohistochemistry on TMAs. As
expected, a significantly higher number of tryptase
mast cells was detected in AITL (average, 9.06; SD, 7.69)
than in PTCL/NOS (average, 2.94; SD, 2.69) samples
(P  0.013; Figure 5, A–D), and many PTCL/NOS cases
did not show the presence of infiltrating mast cells.
Subsequently, to test the relationship between the
amount of infiltrating mast cells and the presence of Th17
cells, the correlation between tryptase and IL-17 cells
was investigated by covariate analysis. The correlation
between tryptase and Foxp3 cells and that between
IL-17 and Foxp3 cells were also analyzed for control
purposes.
No association was found between IL-17 and Foxp3
cells (rho0.107; P 0.391) or between triptase and
Figure 4. Double immunofluorescence confo-
cal microscopy for IL-6 and mast cell tryptase
showing that cells with bright IL-6 expression (A
and D) are reactive to tryptase (B and E). Co-
expression of the two markers is evidenced by
signal overlap (C and F). Release of IL-6 and
tryptase from a degranulating mast cells is
shown in the inset (double indirect immunoflu-
orescence using Alexa 488-conjugated [green
signal] and Alexa 568-conjugated [red signal]
secondary antibodies; original magnifications:
200 [A–F], 1000 [inset]). Microphotographs
are relative to two representative AITL (A–C)
and PTCL/NOS (D–F) cases.
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Foxp3 cells (rho  0.021; P  0.865). Conversely, the
amount of mast cells and Th17 proved to be tightly associ-
ated in our cases as the number of tryptase cells and that
of IL-17 cells showed a high degree of correlation (Spear-
man’s rho  0.737; P  0.0001; Figure 6, A–C).
Besides the association with IL-17-expressing cells,
we decided to test MC correlation with the degree of MVD
in AITL and PTCL/NOS samples, as MCs are known to
participate in tissue remodelling processes, directly influ-
encing angiogenesis through the release of vascular en-
dothelial growth factor and tumor necrosis factor.24 The
MVD resulted significantly higher in AITL as compared
with PTCL/NOS cases (mean, 40.28; SD, 17.41; and
mean, 22.57; SD, 11.09, respectively; P  0.0001). Al-
though a significant association was observed between
the number of MCs and the MVD, this association proved
quite weak (rho  0.242; P  0.02), suggesting that the
pro-angiogenic spur was mainly derived by cellular com-
ponents other than MCs (Figure 6D).
Th17 cells, classically related to granulocyte domi-
nated responses, might exert direct local effects on the
lymphoma microenvironment including that of favoring
granulocyte infiltration and vascular sprouting.25,26 We
thus estimated the amount of infiltrating granulocytes in
AITL and PTCL/NOS samples and tried to correlate it with
the amount of Th17 cells. Similarly, we tested the asso-
ciation between Th17 cells and the MVD.
Granulocytes, as assessed by CD15 immunohisto-
chemistry, were more numerous in AITL than in PTCL/
NOS cases (mean, 40.06; SD, 25.67; and mean, 28.68;
SD, 16.55, respectively) though such difference was
slightly significant (P  0.041). Interestingly, the number
of CD15 granulocytes and that of IL-17 cells proved to
be strongly related (rho  0.806; P  0.0001; Figure 6E).
By contrast, the fraction of Th17 cells was not associated
with the microvascular density (rho  0.242; P  0.062).
These data, along with the evidence of a significant
IL-6 production by mast cells, were indicative of a con-
Figure 5. Amount and distribution of infiltrating mast cells in AITL and
PTCL/NOS cases. A significantly higher number of tryptase-expressing mast
cells are observed infiltrating AITL cases (C and D) as compared with those
infiltrating PTCL/NOS ones (A and B). Mast cells display a scattered distri-
bution and a round-to spindle morphology (Strept-ABC method with amin-
oethylcarbazole chromogen; original magnifications: 100 [A and C]; 200
[B and D]).
Figure 6. Analysis of the associations among regulatory T-cells (Foxp3), Th17 (IL-17), mast cells (tryptase), granulocytes (CD15), and microvascular density
(CD34). A strong linear correlation is found between Th17 and mast cells and between Th17 and granulocytes, whereas the association between mast cells and
microvascular density is slight. Regulatory T-cells do not show significant associations with any of the other variables.
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tribution of mast cells in molding the immunological mi-
croenvironment of AITL by affecting the balance between
regulatory and IL-17-producing T cells.
To further elucidate this hypothesis, the tissue distribution
and reciprocal relationship of MCs, regulatory T-cells, and
IL-17 T cells were investigated by immunohistochemistry
and immunofluorescent confocal microscopy on full sec-
tions from nine representative AITL cases. The scattered
tryptase MCs were frequently found in close contact
with one or more Foxp3 regulatory T-cells indicating the
occurrence of cell–cell interactions between these two
cell types in AITL (Figure 7A). Moreover, lymphocytes in
close contact with MCs commonly expressed OX40, sug-
gesting that the effects of MC-derived IL-6 on neighbor-
ing cells could be complemented by OX40 engagement
from OX40L expressed on MCs (Figure 7B). Consistently,
IL-17-expressing cells were found in proximity to MCs but
direct cell contact was rarely observed (Figure 7C). This
was suggested also by double immunofluorescence for
IL-6 and IL-17, which highlighted IL-17-expressing cells
intermingling with IL-6 ones and preferentially accumu-
lating in AITL cases (Figure 7D). To further confirm that an
actual co-localization between MCs and Th17 occurred,
a spatial co-localization analysis was performed on full
sections that were double-immunostained for tryptase
and IL-17. We assessed the number of Th17 cells out of
eight HPFs comprising four HPFs rich in MCs (indicated
as “High MC” in Figure 8) and four HPFs almost devoid of
MCs (indicated as “Low MC” in Figure 8). In the nine AITL
cases, MCs and Th17 cells proved to be spatially asso-
ciated (rho  0.854; P  0.001) as microscopic fields
with high MC densities showed higher Th17 counts than
those with low MC numbers, which were accordingly
poor in Th17 cells (Figure 8A; see also Supplemental
Figure S3 at http://ajp.amjpathol.org). A similar trend was
observed in the nine representative PTCL/NOS cases
(Figure 8B), though the association proved weak and
barely significant (rho  0.281; P  0.041), this being
consistent with the abovementioned very low prevalence
of Th17 and MCs in PTCL/NOS.
CXCL-13 Is a Candidate for Mast Cell
Accumulation in the AITL Environment
We found that the differential IL-6 expression and Th17
frequency between AITL and PTCL/NOS was related to
the abundance of MCs in the former. However, the rea-
sons for such a preferential MC accumulation in AITL
were obscure. Recent evidences clearly indicate that the
AITL neoplastic clone originates from Tfh cells, a subset
of Th cells characterized by selective homing properties
and germinal-center associated marker expression (ie,
CD10 and Bcl-6).10,20 Tfh cells reside in the follicle where
they provide crucial co-stimulatory signals to B-cells un-
dergoing antigen presentation. Among the features
proper of Tfh cells are the expression of PD-1, ICOS,
CXCR5, and the abundant synthesis of CXCL-13, a po-
tent chemoattractor for B lymphocytes that has been
demonstrated to be essential for germinal-center forma-
tion.27 CXCL-13 mediates expansion of follicular den-
dritic cells and recruitment of B-cells in the germinal
center and exerts an autocrine feedback on Tfh cells
through the interaction with its high-affinity receptor
CXCR5. Since the synthesis of CXCL-13 is maintained in
the AITL neoplastic clone, we investigated whether
CXCL-13 could be responsible for MC recruitment at
sites of infiltration in AITL cases. To address this issue,
we first examined the expression of the CXCL-13 recep-
tors, CXCR3 and CXCR5, by real-time PCR on the human
mast cell line LAD2 by using as positive and negative
controls the BJAB B-cell lymphoma cell line and ADMEC
cells, respectively. Significant mRNA expression of
CXCR5, and to a lesser extent of CXCR3, was detected in
LAD2 cells, and it was slightly lower than that of control
BJAB cells (Figure 9).
Figure 7. A: Tryptase mast cells display cell–cell contact with Foxp3-expressing regulatory T-cells (black arrows). B: Lymphocytes surrounding mast cells
express OX40, suggesting that interactions between mast cells and neighboring T cells can be complemented by OX40 engagement. C: Few mast cells are found
in close contact with IL-17-expressing cells (black arrow). D: A higher density of both IL-6-expressing and IL-17-expressing cells are observed in AITL (upper
panel) than in PTCL/NOS (lower panel) cases, but spatial contact between these two cell types is rarely observed. Pictures are relative to two representative
AITL and one PTCL/NOS cases. A–C: Double immunohistochemistry using alkaline phosphatase anti-alkaline phosphatase and Strept-ABC methods with Fast-red
(purple) and DAB (orange/brown) chromogens, respectively. D: Double indirect immunofluorescence using Alexa 488-conjugated (green signal) and Alexa
568-conjugated (purple signal) secondary antibodies. Original magnifications: 400 (A); 200 (B–D).
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We thus evaluated the capability of LAD2 cells to mi-
grate in response to CXCL-13. The chemotaxis assay
showed that CXCL-13 successfully induced LAD2 mast
cell migration already at the 6 hours time point at a
concentration of 10 ng/ml (Figure 10A). CXCL-13-in-
duced LAD2 cell migration was enhanced at higher con-
centrations of CXCL-13 and at the 24 hours time point,
with a percentage of LAD2 migrating cells slightly lower
than that of BJAB cells (Figure 10B). These results sug-
gest that CXCL-13 is a possible mediator of the prefer-
ential accumulation of MCs in the AITL environment.
Discussion
The neoplastic clone and the non-neoplastic components
of the tumor microenvironment are linked by a dense
network of cellular and molecular interactions. The variety
of such interactions can either contribute to the anti-tumor
host response or even foster tumor growth.28–30 Different
tumor types are associated with different microenviron-
ments, and the environment-related gene signatures have
recently emerged as key determinants in the prognostic
assessment of several hematological neoplasms.31,32 In
most lymphoid malignancies, the composition of the mi-
croenvironment endorses also a diagnostic significance
since it represents one of the main histopathological fea-
tures. In the setting of mature T-cell lymphomas, the
extreme morphological variability of the T-cell clone
makes the distinction between AITL and PTCL/NOS quite
difficult. The histopathological and immunophenotypical
detection of the peculiar features of the AITL microenvi-
ronment is then of great help.8
The most relevant clinical characteristic of AITL is the
high frequency of autoimmune manifestations. These in-
clude skin rash, polyarthritis, pleural effusion, autoim-
mune hemolytic anemia, and thrombocytopenia, all sug-
gestive of a marked dysregulation of the T-cell immune
response.33,34
Figure 8. Results of the MC/Th17 co-localization analysis performed on full
sections from nine AITL (A) and nine PTCL/NOS (B) cases following double
immunostaining for mast cell tryptase and IL-17. In each case, the number of
MCs (light green and light blue bars) and Th17 cells (dark green and dark
blue bars) is reported as assessed in four HPFs with easily countable MCs
(indicated as “High MC”) and in four HPFs almost devoid of MCs (indicated
as “Low MC”). In AITL cases (A) the spatial association between MCs and
Th17 was evident as HPFs rich in MCs displayed higher Th17 counts than
those almost devoid of MCs. Conversely, in PTCL/NOS cases (B), this picture
was less evident owing to the paucity of MCs and Th17 cells.
Figure 9. CXCR3 and CXCR5 expression in the human LAD2 mast cell line.
CXCR3 and CXCR5 mRNA levels in ADMEC, BJAB, and LAD2 cells were
determined by quantitative real-time PCR. Normalized fold expression rep-
resents the concentration ratio between the specific chemokine and the
housekeeping mRNA (GADPH). Data are the mean  SD of two separate
experiments; n.d., nondetected amplificate.
Figure 10. Dose and time response of BJAB and LAD2 cells to CXCL-13-
induced chemotaxis. Chemotaxis of BJAB and LAD2 cells to 10 ng/ml (A) and
100 ng/ml (B) recombinant human CXCL13 at indicated time points is shown.
Data represent mean  SD of two separate experiments performed in
triplicate.
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The Th1/Th2 paradigm has been recently reshaped by
the identification of a subpopulation of IL-17-producing
Th cells whose key role is the induction of autoimmune
responses.19 Studies on the generation of Th17 cells
highlighted the influence of the immunological environ-
ment on the functional plasticity of T lymphocytes as Th17
cells can be induced from naive and regulatory T cells
under the pressure of pro-inflammatory stimuli.35,36 The
required combination of TGF- and IL-1, IL-6, and/or
IL-21 for Th17 induction and expansion suggests that
Th17 generation is a matter of balance between pro- and
anti-inflammatory signals and that in a pro-inflammatory
background even cells with regulatory functions have a
share in triggering autoimmunity.
In this study we assessed the frequency of regulatory
and IL-17-producing T cells in PTCL/NOS and AITL to
test the hypothesis of a different participation of such cell
types in the composition of the lymphoma-associated
microenvironment. We found a higher number of infiltrat-
ing Th17 cells in AITL than in PTCL/NOS cases, whereas
the number of Foxp3 Treg in the two lymphomas was
similar. Accordingly, IL-6, IL-21, and IL-23 cytokines in-
volved in the generation, expansion, and maintenance of
Th17 cells were more represented in AITL than in PTCL/
NOS. Moreover, the finding of a strong association be-
tween Th17 cells and the amount of infiltrating granulo-
cytes supported a role for Th17 cells in influencing the
composition of the inflammatory microenvironment of
AITL lymphomas.
Recently, our group and others demonstrated distinct
molecular features in AITL and PTCL/NOS neoplastic
clones by GEP analysis.2,9,10 In particular, genes belong-
ing to the AITL signature were associated to cell–cell
adhesion and communication, immune response, and
vascular biology.2,9,10,37 In the present study, we could
not detect significant differences between AITL and
PTCL/NOS cases as far as Th17-related cytokine pat-
terns are concerned at mRNA level. This fact, in our
opinion, probably reflected the original case selection,2,9
which included only cases almost exclusively constituted
by neoplastic cells, thus limiting the influences of reactive
components. Consistent with this hypothesis, differences
in IL-6, IL-21, and IL-23 expression were recently re-
corded in other series, which included nonselected sam-
ples sometimes enriched in reactive elements.21 Taken
together such observations suggest that some microen-
vironmental dynamics are likely responsible for cytokine
enrichment in AITL.
IL-6-mediated signals in a TGF-b rich environment can
determine Th17 skewing.19,34 We found MCs strongly
expressing IL-6 and preferentially accumulating in AITL.
MCs showed cell–cell proximity with Foxp3 and OX40-
expressing cells and displayed a significant numeric and
spatial correlation with Th17 cells. MCs have a high de-
gree of functional plasticity38; they synthesize a broad
array of molecules with either pro- (eg, IL-6 and tumor
necrosis factor-) or anti-inflammatory (eg, IL-10) prop-
erties and release them according to the type and
strength of the environmental signals they sense.39
Though classically confined to the role of effectors in
allergic responses, MCs are emerging as master regula-
tors of both innate and adaptive immunity as they play
different roles in the induction, amplification, mainte-
nance, and shutdown of physiological and aberrant re-
sponses.40–42 We and others have recently described
the existence of a bidirectional influence between MCs
and regulatory T-cells in which the OX40/OX40L axis and
soluble mediators are contributing either to the mainte-
nance of self tolerance or to autoimmunity.22,23 In the
setting of autoimmunity, we demonstrated the role of MCs
in the initiation of the pathological immune response in
EAE (the murine model of multiple sclerosis) through the
suppression of Treg cells and their skewing into patho-
genic Th17 cells.23 On these bases, we could speculate
on the involvement of MCs in fostering the pro-inflamma-
tory environment of AITL through the production of IL-6
and the direct interaction with regulatory and effector
T-cells predisposing their shift to Th17 cells. Grippingly,
elevated IL-6 serum levels have been recorded in pa-
tients with AITL, further supporting the role of the IL-6 axis
in the establishment and maintenance of the lymphoma-
associated inflammatory milieu.43–45
Although the actual magnitude and the final effects of
the interactions underlying the different composition of
Figure 11. A schematic representation of the dy-
namics taking place in the AITL microenviron-
ment. AITL neoplastic cells and FDC secrete
CXCL-13 contributing to the recruitment of MCs
and to FDC hyperplasia. MC-derived IL-6, along
with AITL-clone-derived IL-21 and FDC-synthe-
sized IL-23 contribute to the preferential genera-
tion of Th17 cells, which in turn favor granulocyte
accumulation and possibly trigger autoimmune
phenomena.
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the immunological microenvironment of AITL and PTCL/
NOS are obscure, the higher frequency of Th17 cells we
observed in AITL cases could possibly fit with the pref-
erential occurrence of autoimmune disorders in these
patients.37 Such disorders involve the binding of IL-17 to
its receptors widely distributed on parenchymal cells and
the interaction of Th17 cells with other immune effectors
such as polymorphonuclear leukocytes that in our cases
proved tightly associated with Th17 cells.19,46
In this work we also showed that CXCL-13, the primary
chemokine produced by normal Tfh cells, FDCs, and by
AITL neoplastic cells, is able to induce migration of MCs
as they express both CXCR5 and CXCR3 receptors. The
abundant production of CXCL-13 by the AITL neoplastic
clone could likely be responsible for the preferential ac-
cumulation of MCs in the AITL environment. Besides
having a share in the generation of Th17 cells, MCs could
affect the AITL environment through the production of
pro-angiogenic molecules such as vascular endothelial
growth factor and tumor necrosis factor thus contributing
to the deregulated angiogenesis mostly driven by the
neoplastic-clone derived vascular endothelial growth fac-
tor.47 However, the low degree of correlation we ob-
served between MCs and the MVD is in favor of a mar-
ginal role for MCs in the arrangement of the vascular
network of these lymphomas. Moreover, MCs could par-
ticipate into FDC expansion and maturation since MC
exosomes have been reported to induce maturation and
activation of dendritic cells.48
In conclusion, we have shown that the immunological
microenvironment of AITL, differently from that of PTCL/
NOS, is characterized by the abundance of mast cells
likely recruited by CXCL-13, produced, at least in part, by
the neoplastic clone of Tfh derivation. In the AITL envi-
ronment, infiltrating MCs might promote inflammation tip-
ping the balance between immune regulation and auto-
immunity and contributing to the local changes occurring
in AITL-infiltrated tissues (Figure 11). The possible clini-
cal relevance of microenviromental patterns as well as
the potential therapeutic impact of strategies interfering
in such dynamics surely warrant further investigation.
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